KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.…
Industry Peers
BiotechnologyKey Statistics
About Krystal Biotech (NASDAQ: KRYS)
›
Krystal Biotech (NASDAQ: KRYS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 295 employees.
The shares were at 315.82 USD on 19 November 2026, up 57.9% over 52 weeks. Its 52-week range is 192.52 USD to 382.54 USD: the price is 17.4% below the high and 64.0% above the low.
At a market capitalisation of 9.36B USD, it trades at 42.9 times trailing earnings and 34.2 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 28% for KRYS.
Krystal Biotech reports return on equity of 16.8%, an operating margin of 48.4% and revenue up 30.2% year over year.
It holds more cash than debt, a net cash position of 903.26M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 388.22 USD is 22.9% above the current price. The next earnings report is expected on 16 February 2027.